HumaniPSC-DerivedNeuralStemCellsthathavebeengeneticallyeditedusingCRISPR-Cas9technologytointroducetheP301Lmutation(CCG>CTG)intotheMAPTgene.ThislineishomozygousfortheP301Lmutationsobothallelescontainthemutation.Clickontheproductimagestoseethedataandfurtherdetails.
TheP301LmutationMAPThasbeenimplicatedinfrontotemporaldementiaandparkinsonism(Dumanchinetal.,1998).Themutationaffectsonlythe4RisoformsofMAPTsincetheexoncontainingthemutationissplicedoutof3Risoforms(Huttonetal.,1998).AggregatedMAPT/tauproteininaffectedpatientsconsistedmainlyofthe4Risoform(Huttonetal.,1998).TheP301LmutationpromotesaggregationofMAPT/tauproteinintoorderedpairedhelicalfilamentsandbetasheetformationinvitro(vonBergenetal.,2001).
Startingmaterial | Dermalfibroblast |
Donorgender | Female |
Donorageatsampling | 64yrs |
Karyotype | Normal |
Reprogrammingmethod | Episomalvector |
Inductionmethod | Monolayer&chemicallydefinedmedium |
Geneticmodification | HomozygousfortheMAPTP301Lmutation(CCG>CTG) |
Geneticmodification | Containsapuromycinresistancecassette(intronic) |
Size | ≥1.5millioncells |
Kitcomponents | 1vialofNeuralStemCells(≥1.5millioncells)and1bottleofNeuralPlating-XFMedium(30mL) |
Growthproperties | Adherent |
Shippingconditions | Dryice |
Storageconditions | Liquidnitrogen |